EPI (HKG:0689) unit EPI ESG Investment (New Zealand) agreed to provide a NZ$3.1 million loan facility to Fanchen Dou, according to a Thursday Hong Kong bourse filing.
The facility has an interest rate of 6% per annum and a term of eight months.
A first mortgage related to certain lands and properties in Auckland, New Zealand, was pledged as collateral against the loan.
Dynam Japan (HKG:6889) recorded a 35% decline in attributable profit in the year ended March 31 to 2.6 billion yen from 4.01 billion yen a year prior, according to a Thursday Hong Kong bourse filing.The pachinko hall operator's earnings per share slipped to 3.7 yen from 5.8 yen in the previous fiscal year.Revenue slid 2.3% to 123.2 billion yen from 126.1 billion yen in the year-ago period.The firm declared a final dividend of 2.5 yen per ordinary share for the year, payable June 26 to shareholders of record on June 5.
Melbourne Enterprises (HKG:0158) recorded an attributable profit of HK$20.1 million in the six months ended March 31, compared with an attributable loss of HK$141.5 million a year prior, according to a Thursday Hong Kong bourse filing.Earnings per share were HK$0.80, compared with a loss per share of HK$5.66 in the corresponding period of the previous fiscal year.The property investor's revenue slipped slightly to HK$81.5 million from HK$81.9 million in the year-ago period.The firm declared an interim dividend of HK$1.6 per share for the period.
Biotech firm Delta-Fly Pharma (TYO:4598) has completed patient enrolment for the phase 2 portion of its clinical trial testing an experimental drug for pancreatic cancer, according to a Tokyo bourse filing on Thursday.The study, known as DFP-17729, is a double-blind, randomised, placebo-controlled trial that combines the company's drug with TS-1, an existing oral chemotherapy, in patients with advanced or recurrent pancreatic cancer that cannot be surgically removed.The trial uses an adaptive design, meaning the results from the phase 2 portion will determine how many patients are needed for the phase 3 portion. If the drug shows a clear benefit in overall survival, the study can move quickly into the next phase.If successful, DFP-17729 could offer patients a new treatment option that is taken orally, has a strong safety profile, and is cost-effective. The drug works by neutralising the acidic environment around tumours, which helps slow cancer growth without the serious side effects often seen with other treatments.